Last reviewed · How we verify
rhGM-CSF
At a glance
| Generic name | rhGM-CSF |
|---|---|
| Also known as | GM-CSF, granulocyte-macrophage colony-stimulating factor, Recombinant human granulocyte macrophage stimulating factor, Topleucon®, Granulocyte Macrophage Colony Stimulating Factor |
| Sponsor | University of Wisconsin, Madison |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP). (PHASE3)
- The Safety, Tolerability, and Efficacy of KD01 in Gynecologic Malignancies (PHASE1)
- Molgramostim Nebulizer Solution Expanded Access Program Protocol
- Effectiveness of a rhGM-CSF-containing Gel on Promoting Recovery After 1927-nm Fractional Thulium Fiber Laser Treatment of Atrophic Acne Scars. (NA)
- Macrophage Stimulating Factor in the Treatment of Diabetic Wounds (NA)
- Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (PHASE3)
- pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer (PHASE2)
- Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) Inhalation to Improve Host Defense and Pulmonary Barrier Restoration (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rhGM-CSF CI brief — competitive landscape report
- rhGM-CSF updates RSS · CI watch RSS
- University of Wisconsin, Madison portfolio CI